Natural Product (NP) Details
General Information of the NP (ID: NP3369) | |||||
---|---|---|---|---|---|
Name |
Neferine
|
||||
Synonyms |
Neferine; 2292-16-2; Neferin; 4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[[(1R)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl]oxy]phenol; BRN 1523459; CHEMBL455560; SCHEMBL12807595; DTXSID40177462; CHEBI:176257; ZINC6017976; AKOS016002114; Phenol, 4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)-2-((1,2,3,4-tetrahydro-6-methoxy-1-((4-methoxyphenyl)methyl)-2-methyl-7-isoquinolinyl)oxy)-; X1192; A14743; 292N162; Q-100292; 4-{[(1R)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydro-1-isoquinolinyl]methyl}-2-{[(1R)-6-methoxy-1-(4-methoxybenzyl)-2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl]oxy}phenol
Click to Show/Hide
|
||||
Species Origin | Nelumbo nucifera ... | Click to Show/Hide | |||
Nelumbo nucifera | |||||
Disease | Lung cancer [ICD-11: 2C25] | Investigative | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C38H44N2O6
|
||||
PubChem CID | |||||
Canonical SMILES |
CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)OC)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC
|
||||
InChI |
1S/C38H44N2O6/c1-39-15-14-27-21-36(44-5)38(23-30(27)31(39)17-24-7-10-28(42-3)11-8-24)46-34-19-25(9-12-33(34)41)18-32-29-22-37(45-6)35(43-4)20-26(29)13-16-40(32)2/h7-12,19-23,31-32,41H,13-18H2,1-6H3/t31-,32-/m1/s1
|
||||
InChIKey |
MIBATSHDJRIUJK-ROJLCIKYSA-N
|
||||
CAS Number |
CAS 2292-16-2
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
Experimental
Result(s) |
Snail overexpression or TGF-Beta1-induced EMT attenuated Neferine-mediated OXA sensitization in HCC. | |||||
TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Neferine treatment effectively promotes TRAIL-mediated cell death and this effect likely occurs via the autophagic flux and the JNK pathway. | |||||
Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Phosphorylation | MCL1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Bone marrow mononuclear cells derived from chronic myeloid leukemia patients | Chronic myeloid leukemia | Homo sapiens | |||
Experimental
Result(s) |
These results suggest that neferine might be a potential imatinib sensitizer in CML treatment. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
Neferine reduces cisplatin-induced nephrotoxicity by enhancing autophagy via the AMPK/mTOR signaling pathway. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Neferine acts as an effective enhancer of DOX-induced cell death in A549 cells through ROS mediated apoptosis with MAPK activation and inhibition of NF-KappaB nuclear translocation. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Molecule Info | [7] | |
Ribosomal protein S6 kinase beta-1 (S6K1) | Molecule Info | [8] | ||
KEGG Pathway | Protein processing in endoplasmic reticulum | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | HIF-1 signaling pathway | |||
4 | mTOR signaling pathway | |||
5 | PI3K-Akt signaling pathway | |||
6 | AMPK signaling pathway | |||
7 | TGF-beta signaling pathway | |||
8 | Fc gamma R-mediated phagocytosis | |||
9 | Insulin signaling pathway | |||
10 | Proteoglycans in cancer | |||
11 | Acute myeloid leukemia | |||
12 | Choline metabolism in cancer | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | Click to Show/Hide | ||
2 | PDGF signaling pathway | |||
3 | PI3 kinase pathway | |||
4 | p53 pathway by glucose deprivation | |||
5 | CCKR signaling map ST | |||
Pathwhiz Pathway | Leucine Stimulation on Insulin Signaling | Click to Show/Hide | ||
Pathway Interaction Database | Insulin Pathway | Click to Show/Hide | ||
2 | IL4-mediated signaling events | |||
3 | CDC42 signaling events | |||
4 | Angiopoietin receptor Tie2-mediated signaling | |||
5 | Regulation of Telomerase | |||
6 | mTOR signaling pathway | |||
7 | IGF1 pathway | |||
8 | IL2 signaling events mediated by PI3K | |||
9 | Integrins in angiogenesis | |||
10 | RXR and RAR heterodimerization with other nuclear receptor | |||
11 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
12 | a6b1 and a6b4 Integrin signaling | |||
13 | TGF-beta receptor signaling | |||
Reactome | mTORC1-mediated signalling | Click to Show/Hide | ||
WikiPathways | Oxidative Stress | Click to Show/Hide | ||
2 | Transcriptional activation by NRF2 | |||
3 | NRF2 pathway | |||
4 | Nuclear Receptors Meta-Pathway | |||
5 | Aryl Hydrocarbon Receptor Pathway | |||
6 | Mesodermal Commitment Pathway | |||
7 | Aryl Hydrocarbon Receptor | |||
8 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
9 | Arylhydrocarbon receptor (AhR) signaling pathway | |||
10 | ErbB Signaling Pathway | |||
11 | Interferon type I signaling pathways | |||
12 | G13 Signaling Pathway | |||
13 | IL-2 Signaling Pathway | |||
14 | Insulin Signaling | |||
15 | Cytoplasmic Ribosomal Proteins | |||
16 | EGF/EGFR Signaling Pathway | |||
17 | IL-4 Signaling Pathway | |||
18 | IL-6 signaling pathway | |||
19 | Kit receptor signaling pathway | |||
20 | Apoptosis-related network due to altered Notch3 in ovarian cancer | |||
21 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
22 | BDNF signaling pathway | |||
23 | Interleukin-11 Signaling Pathway | |||
24 | FSH signaling pathway | |||
25 | Leptin signaling pathway | |||
26 | TSH signaling pathway | |||
27 | Signaling by Insulin receptor | |||
28 | TOR Signaling | |||
29 | AMPK Signaling | |||
30 | IL-5 Signaling Pathway |




